Article info
PDFOriginal research
Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival
- Correspondence to Dr Russell R Broaddus, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599, USA; rbroaddus{at}med.unc.edu
Citation
Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival
Publication history
- Received December 30, 2021
- Accepted April 14, 2022
- First published April 28, 2022.
Online issue publication
November 15, 2022
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.